Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Running, not enrolling · Phase 2

Conditions studied: Renal Cell Carcinoma

In brief

All patients will receive IL-2 (14 planned doses with an additional cycle 14 days after the first). Responding patients with regressing disease are eligible for up to 6 IL-2 cycles. Patients assigned to SBRT arm will receive two doses of SBRT on the Wednesday and Friday before the Monday on which IL-2 starts.

Key facts

Study ID

NCT02306954

Run by

Providence Health & Services

People needed

84

Starts

2014-12-01

Expected to finish

2026-12-01

Last updated by the study team

2026-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histological confirmation of predominant conventional (clear cell) renal cancer
• Patients must be ≥ 18 years of age
• Tumors amenable to SBRT in lungs (central locations preferred), mediastinum, chest wall, bones with a soft tissue component (other than long bones), or liver, liver hilum and associated lymph nodes (inclusive of immediately adjacent masses), 1 - 3 foci; no minimum size, but none greater than 7 cm. Patients may have other metastases but only a maximum of 3 will be treated
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of protocol treatment. In addition, women of childbearing potential as well as male patients must agree to take appropriate precautions to avoid pregnancy
• Patients must agree to participate in the Prometheus IL-2 patient registry (PROCLAIM registry)
• Patients must sign a study-specific consent form

You may not qualify if…

• No metastatic site amenable to SBRT
• Patients with brain metastases not candidates for radiosurgery alone
• Previous radiation to sites proposed for SBRT
• Patients with active systemic, pulmonary, or pericardial infection
• Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus
• Evidence of ischemia on exercise tolerance test, stress thallium study, or baseline EKG
• Clinically significant underlying pulmonary disease as measured by pulmonary function tests
• Blood tests within protocol-specified range
• Need for chronic steroids

Where it is running

• Portland Providence Medical Center — Portland, Oregon, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.